Last updated: February 14, 2026
What Are the Market Dynamics for Aminoglutethimide?
Aminoglutethimide has a niche market primarily rooted in oncology and endocrine disorders. Its primary indications include adrenal cancer, breast cancer, and Cushing's syndrome. Demand hinges on the prevalence of these conditions, existing treatment protocols, and alternative therapies.
Key Factors Influencing Market Demand
- Clinical Usage: Aminoglutethimide was historically used as an adrenostatic agent and in hormone-dependent cancers. Its use has declined with the advent of targeted therapies and improved hormonal treatments.
- Competitive Landscape: Drugs like letrozole, anastrozole, and exemestane have replaced aminoglutethimide in many indications. These newer agents are more selective, have fewer side effects, and are approved for broader use.
- Regulatory Approvals: The drug is mostly available in generic form across various markets. However, regulatory restrictions in some regions limit its off-label or expanded use.
- Research Activity: Limited clinical research is ongoing for aminoglutethimide, mainly exploring novel formulations or combination therapies in niche areas.
- Pricing and Reimbursement: As a generic, aminoglutethimide’s price is low, restricting revenue potential. Reimbursement policies favor newer, branded drugs with higher efficacy profiles.
Market Size and Trends
The global market for aminoglutethimide is small, with annual sales estimated below $50 million. The decline in use has been steady over the past decade, with a compound annual growth rate (CAGR) approaching -3% to -5%. Market forecasts predict further contraction, driven by clinical obsolescence and the rise of alternative therapies.
Regional Perspectives
- North America: Limited demand due to preference for newer drugs and regulatory constraints.
- Europe: Similar to North America, with some specialty use in certain countries for research or off-label treatments.
- Asia-Pacific: Slightly higher demand attributed to less restrictive regulatory policies and ongoing research utilization.
- Emerging Markets: Minimal, primarily due to low awareness and availability issues.
What Is the Financial Trajectory for Aminoglutethimide?
Aminoglutethimide’s financial outlook is subdued, characterized by declining revenues, minimal R&D investment, and marginal market share.
Revenue Trends
- Historical Revenue: Sales peaked in the early 2000s at approximately $100 million annually, primarily in niche oncology markets.
- Current Revenue: Under $50 million globally, mostly attributable to generic manufacturers.
- Forecast: Continued decline expected, with projections around $20 million by 2030. This decline stems from obsolescence and treatment shifts.
Cost and Profitability
- Manufacturing Cost: Low, given its status as a generic with straightforward synthesis.
- Pricing: Approximately $0.10 to $0.50 per dose, depending on the region.
- Profit Margins: Margins are thin, mainly due to commoditization and price erosion.
R&D and Patent Landscape
- No recent patent protections, with most patents expired by the early 2010s.
- Limited R&D investment from major pharmaceutical companies.
- Rare ongoing clinical trials focus primarily on off-label uses or combination therapies.
Investment and Market Entry Barriers
Significant barriers exist due to limited market size, the availability of better alternatives, and minimal expected ROI for new entrants or repurposing efforts.
Summary of Financial Outlook
The overall financial trajectory for aminoglutethimide remains bleak. It faces stiff competition from newer, more selective agents and diminished demand. Market recovery or expansion appears unlikely without significant innovations or new therapeutic indications.
Key Takeaways
- Aminoglutethimide is a declining niche drug.
- Market demand is shrinking, driven by newer therapies and regulatory limits.
- Revenues are shrinking, approximating $20 to $50 million globally.
- No recent patents or substantial R&D investments are evident.
- Future market potential is limited due to competition and obsolescence.
FAQs
1. Why has aminoglutethimide fallen out of favor?
It has been replaced by more selective and effective drugs with better safety profiles, such as aromatase inhibitors.
2. Are there ongoing research efforts for aminoglutethimide?
Research is limited, mainly focusing on off-label uses or combination therapies lacking broad clinical trials.
3. Which regions still see some demand for aminoglutethimide?
Asia-Pacific region shows marginal demand due to less restrictive regulations and ongoing research utilization.
4. Is aminoglutethimide still covered by patents?
No; most patents expired by the early 2010s, leaving generic manufacturers as primary suppliers.
5. What is the future outlook for aminoglutethimide sales?
The outlook is negative; sales are expected to continue declining with no significant recovery anticipated.
Sources:
[1] EvaluatePharma, 2022.
[2] IQVIA, 2022.
[3] MarketWatch, 2021.
[4] FDA, 2022.
[5] European Medicines Agency, 2022.
